

Christophe Duvoux

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9395715/publications.pdf>

Version: 2024-02-01

40
papers

3,491
citations

331670

21
h-index

302126

39
g-index

41
all docs

41
docs citations

41
times ranked

4733
citing authors

#	ARTICLE	IF	CITATIONS
1	R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation. <i>JHEP Reports</i> , 2022, 4, 100445.	4.9	6
2	Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European Study. <i>Gastroenterology</i> , 2021, 160, 1151-1163.e3.	1.3	130
3	International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria. <i>JHEP Reports</i> , 2021, 3, 100331.	4.9	10
4	2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 583-605.	3.7	27
5	Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation. <i>Journal of Hepatology</i> , 2021, 75, S178-S190.	3.7	30
6	Early transplantation maximizes survival in severe acute-on-chronic liver failure: Results of a Markov decision process model. <i>JHEP Reports</i> , 2021, 3, 100367.	4.9	21
7	Socioeconomic Deprivation Does Not Impact Liver Transplantation Outcome for HCC: A Survival Analysis From a National Database. <i>Transplantation</i> , 2021, 105, 1061-1068.	1.0	6
8	Comment on "Shadows Behind Using Simple Risk Models in Selection of Hepatocellular Carcinoma Patients for Liver Transplantation". <i>Annals of Surgery</i> , 2021, 274, e832-e833.	4.2	0
9	Temporal Trends and Outcomes in Liver Transplantation for Recipients With HIV Infection in Europe and United States. <i>Transplantation</i> , 2020, 104, 2078-2086.	1.0	24
10	Reply to Rodriguez-Peralvarez et al. <i>Transplant International</i> , 2020, 33, 1825-1826.	1.6	1
11	Influence of everolimus-based treatment on circulating regulatory T cells after liver transplantation: Comparative study with tacrolimus-based therapy. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 45, 101559.	1.5	6
12	Liver transplantation in patients with sickle cell disease: possible but challenging—a cohort study. <i>Transplant International</i> , 2020, 33, 1220-1229.	1.6	10
13	COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 724-725.	8.1	72
14	Impact of COVID-19 on liver transplantation in Europe: alert from an early survey of European Liver and Intestine Transplantation Association and European Liver Transplant Registry. <i>Transplant International</i> , 2020, 33, 1244-1252.	1.6	48
15	Liver Resection for Solitary Transplantable Hepatocellular Carcinoma: The Role of AFP Score. <i>World Journal of Surgery</i> , 2019, 43, 221-229.	1.6	5
16	Anonymous living donation in liver transplantation: Squaring the circle or condemned to vanish?. <i>Journal of Hepatology</i> , 2019, 71, 864-866.	3.7	3
17	Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study. <i>Journal of Hepatology</i> , 2019, 71, 313-322.	3.7	212
18	Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma. <i>International Journal of Cancer</i> , 2019, 144, 886-896.	5.1	22

#	ARTICLE	IF	CITATIONS
19	A Multicenter, Prospective, Observational Study of Conversion from Twice-Daily Immediate-Release to Once-Daily Prolonged-Release Tacrolimus in Liver Transplant Recipients in France: The COBALT Study. <i>Annals of Transplantation</i> , 2019, 24, 506-516.	0.9	5
20	Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 336-344.	3.7	47
21	Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series. <i>Digestive and Liver Disease</i> , 2018, 50, 668-674.	0.9	24
22	12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation. <i>Hepatology</i> , 2018, 68, 1277-1287.	7.3	11
23	Survival of children after liver transplantation for hepatocellular carcinoma. <i>Liver Transplantation</i> , 2018, 24, 246-255.	2.4	32
24	2018 Annual Report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation. <i>Transplant International</i> , 2018, 31, 1293-1317.	1.6	325
25	Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. <i>Journal of Hepatology</i> , 2018, 69, 810-817.	3.7	199
26	Predictive Factors for Survival in Children Receiving Liver Transplants for Wilson's Disease: A Cohort Study Using European Liver Transplant Registry Data. <i>Liver Transplantation</i> , 2018, 24, 1186-1198.	2.4	15
27	Delisting of HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting. <i>Liver International</i> , 2018, 38, 2170-2177.	3.9	54
28	Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. <i>Journal of Hepatology</i> , 2017, 66, 552-559.	3.7	166
29	ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. <i>Journal of Hepatology</i> , 2017, 67, 585-602.	3.7	71
30	Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study. <i>American Journal of Transplantation</i> , 2017, 17, 2869-2878.	4.7	6
31	Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America. <i>Liver International</i> , 2016, 36, 1657-1667.	3.9	71
32	Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. <i>Journal of Hepatology</i> , 2016, 65, 524-531.	3.7	298
33	Functional imaging of hepatocellular carcinoma using diffusion-weighted MRI and 18F-FDG PET/CT in patients on waiting-list for liver transplantation. <i>Cancer Imaging</i> , 2016, 16, 4.	2.8	21
34	Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors. <i>Digestive and Liver Disease</i> , 2015, 47, 869-876.	0.9	46
35	Liver Transplantation for Hepatocellular Carcinoma: A Model Including α -Fetoprotein Improves the Performance of Milan Criteria. <i>Gastroenterology</i> , 2012, 143, 986-994.e3.	1.3	736
36	What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma?. <i>Liver Transplantation</i> , 2011, 17, S147-S158.	2.4	13

#	ARTICLE	IF	CITATIONS
37	Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients. <i>Liver Transplantation</i> , 2006, 12, 1489-1495.	2.4	27
38	Impact of UCSF criteria according to pre- and post-OLT tumor features: Analysis of 479 patients listed for HCC with a short waiting time. <i>Liver Transplantation</i> , 2006, 12, 1761-1769.	2.4	405
39	Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patients. <i>World Journal of Gastroenterology</i> , 2006, 12, 7319.	3.3	70
40	Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. <i>Liver Transplantation</i> , 2005, 11, 767-775.	2.4	216